158 related articles for article (PubMed ID: 38519009)
21. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
[TBL] [Abstract][Full Text] [Related]
22. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
Shea YF; Ha J; Chu LW
Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
[TBL] [Abstract][Full Text] [Related]
23. Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias.
Shellikeri S; Cho S; Cousins KAQ; Liberman M; Howard E; Balganorth Y; Weintraub D; Spindler M; Deik A; Lee EB; Trojanowski JQ; Irwin D; Wolk D; Grossman M; Nevler N
Parkinsonism Relat Disord; 2022 Sep; 102():94-100. PubMed ID: 35985146
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.
Gmitterová K; Gawinecka J; Llorens F; Varges D; Valkovič P; Zerr I
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):461-470. PubMed ID: 30083957
[TBL] [Abstract][Full Text] [Related]
25. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
Mollenhauer B; Bibl M; Wiltfang J; Steinacker P; Ciesielczyk B; Neubert K; Trenkwalder C; Otto M
Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906
[TBL] [Abstract][Full Text] [Related]
26. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
[TBL] [Abstract][Full Text] [Related]
29. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
Schaeffer MJ; Callahan BL;
J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
[TBL] [Abstract][Full Text] [Related]
30. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
[TBL] [Abstract][Full Text] [Related]
31. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
32. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
[TBL] [Abstract][Full Text] [Related]
33. Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load.
Chong JR; Chai YL; Lee JH; Howlett D; Attems J; Ballard CG; Aarsland D; Francis PT; Chen CP; Lai MK
J Alzheimers Dis; 2017; 56(1):157-166. PubMed ID: 27911312
[TBL] [Abstract][Full Text] [Related]
34. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.
Barba L; Abu-Rumeileh S; Halbgebauer S; Bellomo G; Paolini Paoletti F; Gaetani L; Oeckl P; Steinacker P; Massa F; Parnetti L; Otto M
Neurology; 2023 Jul; 101(1):e50-e62. PubMed ID: 37188538
[TBL] [Abstract][Full Text] [Related]
35. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
36. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.
Vijayaraghavan S; Maetzler W; Reimold M; Lithner CU; Liepelt-Scarfone I; Berg D; Darreh-Shori T
Alzheimers Dement; 2014 Sep; 10(5):530-540.e1. PubMed ID: 23978325
[TBL] [Abstract][Full Text] [Related]
37. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.
Walker L; McAleese KE; Thomas AJ; Johnson M; Martin-Ruiz C; Parker C; Colloby SJ; Jellinger K; Attems J
Acta Neuropathol; 2015 May; 129(5):729-48. PubMed ID: 25758940
[TBL] [Abstract][Full Text] [Related]
38. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.
Andersson M; Zetterberg H; Minthon L; Blennow K; Londos E
Int J Geriatr Psychiatry; 2011 Jan; 26(1):100-5. PubMed ID: 21157855
[TBL] [Abstract][Full Text] [Related]
39. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
Mollenhauer B; Cepek L; Bibl M; Wiltfang J; Schulz-Schaeffer WJ; Ciesielczyk B; Neumann M; Steinacker P; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Dement Geriatr Cogn Disord; 2005; 19(2-3):164-70. PubMed ID: 15637452
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
